Polymer-free drug-coated coronary stents are cost-effective in patients at high bleeding risk: economic evaluation of the LEADERS FREE trial Filipovic-Pierucci A, Durand-Zaleski I, Butel T, Greene S, Hovasse T, Iniguez A, Nazzaro M, Oldroyd K, Talwar S, Richardt G, Windhovel U, Urban P, Morice M February 20, 2018 | 10.4244/EIJ-D-17-00286
New issue Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue (Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right)) December 6, 2019
Trials Book Discover 5 new trials: GALILEO, CONDI-2/ERIC-PCI, EVOLUTE II-5 years, SCOPE and Excel 5 years (The Trials book is supported by Biotronik) December 13, 2019
Editorial 2019 – A leap year for valvular heart disease (Course directors PCR London Valves 2019) November 15, 2019